Humana is displaying robust revenue growth and expanding margins, driven by strong demand in core markets. Read more on why ...

This performance contributes to Humana’s impressive 10.1% revenue growth over the last twelve months, with the company generating a healthy 8% free cash flow yield. Strategic Initiatives and ...

UNH stock is down sharply. Is this a buying opportunity or a red flag? Understand UnitedHealth's sell-off to make informed ...

In a report released today, Ann Hynes from Mizuho Securities reiterated a Buy rating on Humana (HUM – Research Report), with a price target of $316.00. The company’s shares op ...

In a report released today, Jason Cassorla from Guggenheim maintained a Buy rating on Humana (HUM – Research Report), with a price target of $326.00. The company’s shares clos ...

This performance contributes to Humana’s impressive 10.1% revenue growth over the last twelve months, with the company generating a healthy 8% free cash flow yield. Strategic Initiatives and Growth ...

Investors long trusted UnitedHealth to deliver earnings beats, despite limited transparency. Now they want answers.

This was the stock's second consecutive day of losses.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Calamos Phineus Long/Short Fund rose 0.93% in Q1 (Class I shares at NAV), compared with a price decline of -4.27% for the S&P ...